Cenicriviroc

DB11758InvestigationalSmall molecule

Cenicriviroc has been used in trials studying the treatment of HIV-infection/AIDS, AIDS Dementia Complex, Nonalcoholic Steatohepatitis, Human Immunodeficiency Virus, and HIV-1-Associated Cognitive Motor Complex.

Mechanism: Pharmacologically active on C-C chemokine receptor type 5 and C-C chemokine receptor type 2
Curator reviewed
Formula / weight: C₄₁H₅₂N₄O₄S · 696.95 g/mol (avg)
Code names: TBR 652

Resolves to

Compound

UNII15C116UA4YCAS497223-25-3ChEMBLCHEMBL2110727PubChem11285792

Structure

InChIKeyPNDKCRDVVKJPKG-WHERJAGFSA-NSMILESCCCCOCCOC1=CC=C(C=C1)C1=CC2=C(C=C1)N(CC(C)C)CCC\C(=C/2)C(=O)NC1=CC=C(C=C1)[S@@](=O)CC1=CN=CN1CCC

Targets

P51681CCR5P41597CCR2

What you can answer from here — as of September 23, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

14Drug interactionsStructured to mechanism, not free text

17Clinical trialsPhase, status and sponsor resolved per trial

10+ReferencesStructured and connected to the statements they support

Which drugs share a target with Cenicriviroc, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account